Citation, DOI & article data
Oligoastrocytomas is a historical term no longer recognized in the current WHO classification of CNS tumors previously to denote intracranial tumors that are part of the glial cell continuum, with mixed oligodendroglial and astrocytic cell populations based on histological features and typically occurred in young adults.
The literature is somewhat conflicted on these entities, with imaging appearance and incidence varying widely.
Historically these tumors at some institutions had been encountered commonly, in some instances accounting for 50% of all oligodendrogliomas and considered the third most common glial neoplasm 2. At other sites they were rare. Due to the vague criteria for their definition and wide interobserver variability, however, it is not possible to infer a reliable incidence of oligoastrocytomas 6.
The updated 4th edition (2016) to the WHO classification of CNS tumors required molecularly distinct populations of both components to be identified: astrocytic (IDH-mutant, ATRX-mutant, 1p19q-intact) and oligodendrocytic (IDH-mutant, ATRX-wildtype, 1p19q co-deleted) 8.
In the more recent 5th edition (2021) the term oligoastrocytoma is no longer recognized as a distinct diagnosis 9.
- 1. Naugle DK, Duncan TD, Grice GP. Oligoastrocytoma. Radiographics. 2004;24 (2): 598-600. Radiographics (full text) - doi:10.1148/rg.242035069 - Pubmed citation
- 2. Koeller KK, Rushing EJ. From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics. 2005;25 (6): 1669-88. Radiographics (full text) - doi:10.1148/rg.256055137 - Pubmed citation
- 3. Shaw EG, Scheithauer BW, O'Fallon JR et-al. Oligodendrogliomas: the Mayo Clinic experience. J. Neurosurg. 1992;76 (3): 428-34. doi:10.3171/jns.1992.76.3.0428 - Pubmed citation
- 4. Smith JS, Perry A, Borell TJ et-al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000;18 (3): 636-45. Pubmed citation
- 5. Chen R, Ravindra VM, Cohen AL et-al. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015;38 (3): E2. doi:10.3171/2015.1.FOCUS14745 - Pubmed citation
- 6. Mueller W, Hartmann C, Hoffmann A et-al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am. J. Pathol. 2002;161 (1): 313-9. doi:10.1016/S0002-9440(10)64183-1 - Free text at pubmed - Pubmed citation
- 7. Hoang-Xuan K, Capelle L, Kujas M et-al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 2004;22 (15): 3133-8. doi:10.1200/JCO.2004.10.169 - Pubmed citation
- 8. Louis DN, Perry A, Reifenberger G et-al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131 (6): 803-20. doi:10.1007/s00401-016-1545-1 - Pubmed citation
- 9. Louis D, Perry A, Wesseling P et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro Oncol. 2021;23(8):1231-51. doi:10.1093/neuonc/noab106